Atezolizumab (anti-PD-L1) - Primary antibody, INHIBITOR of Programmed cell death 1 ligand 1 inhibitor, INHIBITOR of Programmed cell death 1 ligand 1 inhibitor

CAS: 1380723-44-3 Cat. No.: A411996 PubChem CID: 168009942

GRADE & PURITY Animal Free, ≥95%, See COA

Application

Flow Cytometry

Host species

Human

Reactive species

Human

Isotype

Human IgG1

Conjugation

Unconjugated

Overview

A human, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).

Specifications

Product Name

Atezolizumab (anti-PD-L1) - Primary antibody, INHIBITOR of Programmed cell death 1 ligand 1 inhibitor

Synonyms

MPDL3280A

Specifications & Purity

Animal Free, ≥95%, See COA

Host species

Human

Conjugation

Unconjugated

Grade

Animal Free

Action Type

INHIBITOR

Mechanism of action

INHIBITOR of Programmed cell death 1 ligand 1 inhibitor

Concentration

See COA

CAS

1380723-44-3

Storage and Shipping

Storage

Protected from light,Store at -20°C

Shipped In

Ice chest + Ice pads

Stability And Storage

The diluted protein solution can be stored in cold storage at 2-8 degrees away from light for no more than 2 weeks. Long-term storage is not recommended. Avoid repeated freeze-thaw. The activity of freeze-thaw protein will decrease by about 5% each time.

Images

ELISA: Atezolizumab (anti-PD-L1) (A411996)

Atezolizumab (anti-PD-L1) (A411996) - ELISA

Immobilized Recombinant Human PD-L1 Protein (rp169666) at 1.0 μg/mL can bind Atezolizumab (anti-PD-L1) (A411996) with the EC₅₀ of 8.37 ng/mL.

Flow Cytometry: Atezolizumab (anti-PD-L1) (A411996)

Atezolizumab (anti-PD-L1) (A411996) - Flow Cytometry

Flow Cytometry analysis of MDA-MB-231 cells labelling PD-L1 (red) with Atezolizumab (anti-PD-L1) (A411996) at 0.2 μg/mL for 1 hour at 4°C and detected with AF 488 - conjugated affinipure goat anti - Human IgG. Blue - Human IgG Isotype Control Antibody (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

Associated Targets(Human)

CD274 Tclin Programmed cell death 1 ligand 1 (0 Activities)

Discover Target: CD274

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Mechanisms of Action

References

1. Yingchun Zeng, Jingxuan Yang, Ka Wang, Huan Xu, Yue Zheng, Songxin Guo, Jingwen Luo, Sha Liu, Xin Ming, Xue Ying.  (2025)  Multifunctional Polymeric Nanoparticles Codelivering Paclitaxel and Monoclonal Antibodies for Triple Combination Therapy of Colorectal Cancer.  BIOMACROMOLECULES,      [PMID:41246989] [10.1021/acs.biomac.5c01421]